KalVista Pharmaceuticals delivered a positive third quarter, demonstrating steady adoption of EKTERLY and expanding its global footprint with multiple regulatory approvals, positioning the company well for growth in the HAE treatment landscape.

• EKTERLY adoption in the U.S. is strong, with utilization aligned with expectations for treating HAE attacks.
• Successful launch in Germany and recent approval in Australia, contributing to an expanding international market presence.
• KONFIDENT-KID trial confirms high treatment satisfaction and rapid symptom relief in pediatric patients aged 2 to 11, with plans for an NDA submission in Q3 2026.
• Recent data showcases a decline in the need for injectable treatments, indicating growing patient confidence in EKTERLY.
• Company is fully financed through profitability following a successful convertible note offering, allowing focus on EKTERLY’s launch and strategic growth opportunities.